Advertisement

Tumor Biology

, Volume 34, Issue 5, pp 3239–3243 | Cite as

Prognostic significance of mammalian sterile 20-like kinase 1 in breast cancer

  • Xiaoyan Lin
  • Fengfeng Cai
  • Xiaoyan Li
  • Xiaoli Kong
  • Cheng Xu
  • Xiaoming Zuo
  • Qifeng Yang
Research Article

Abstract

Mammalian sterile 20-like kinase 1 (Mst1) has been proved in the process of apoptosis and tumor suppression. The aim of the study was to investigate the expression of Mst1 in breast cancer and to evaluate its prognostic significance. The expression of Mst1 was examined in 110 breast cancer patients by immunohistochemistry, in which 80 (72.7 %) were defined as positive for Mst1 expression. Patients with negative expression of Mst1 had poor overall survival, comparing with those with positive expression using Kaplan–Meier survival analysis (P = 0.009). Multivariate analysis using Cox proportional hazards model showed that Mst1 expression was a significant independent prognostic factor in breast cancer (P = 0.030). Our results presented the tumor suppressive role of Mst1, and confirmed Mst1 was a prognostic factor in human breast cancer.

Keywords

Mst1 Breast cancer Prognosis Immunohistochemistry 

Notes

Conflicts of interest

None.

References

  1. 1.
    Cai FF, Kohler C, Zhang B, Wang MH, Chen WJ, Zhong XY. Epigenetic therapy for breast cancer. Int J Mol Sci. 2011;12:4465–87.PubMedCentralCrossRefPubMedGoogle Scholar
  2. 2.
    Xu C, Wang J, Li J, Fang R. Expression of elongation factor (EF)-Tu is correlated with prognosis of gastric adenocarcinomas. Int J Mol Sci. 2011;12:6645–55.PubMedCentralCrossRefPubMedGoogle Scholar
  3. 3.
    Cinar B, Fang PK, Lutchman M, et al. The proapoptotic kinase Mst1 and its caspase cleavage products are direct inhibitors of Akt1. EMBO J. 2007;26:4523–34.PubMedCentralCrossRefPubMedGoogle Scholar
  4. 4.
    Chae HZ, Oubrahim H, Park JW, Rhee SG, Chock PB. Protein glutathionylation in the regulation of peroxiredoxins: a family of thiol-specific peroxidases that function as antioxidants, molecular chaperones, and signal modulators. Antioxid Redox Signal. 2012;16:506–23.PubMedCentralCrossRefPubMedGoogle Scholar
  5. 5.
    Qiao M, Wang Y, Xu X, et al. Mst1 is an interacting protein that mediates PHLPPs' induced apoptosis. Mol cell. 2010;38:512–23.CrossRefPubMedGoogle Scholar
  6. 6.
    Yuan Z, Kim D, Shu S, et al. Phosphoinositide 3-kinase/Akt inhibits MST1-mediated proapoptotic signaling through phosphorylation of threonine 120. J Biol Chem. 2010;285:3815–24.PubMedCentralCrossRefPubMedGoogle Scholar
  7. 7.
    Creasy CL, Chernoff J. Cloning and characterization of a human protein kinase with homology to Ste20. J Biol Chem. 1995;270:21695–700.CrossRefPubMedGoogle Scholar
  8. 8.
    Huang J, Wu S, Barrera J, Matthews K, Pan D. The Hippo signaling pathway coordinately regulates cell proliferation and apoptosis by inactivating Yorkie, the Drosophila Homolog of YAP. Cell. 2005;122:421–34.CrossRefPubMedGoogle Scholar
  9. 9.
    Graves JD, Gotoh Y, Draves KE, et al. Caspase-mediated activation and induction of apoptosis by the mammalian Ste 20-like kinase Mst1. EMBO J. 1998;17:2224–34.PubMedCentralCrossRefPubMedGoogle Scholar
  10. 10.
    Ura S, Masuyama N, Graves JD, Gotoh Y. MST1-JNK promotes apoptosis via caspase-dependent and independent pathways. Genes cells. 2001;6:519–30.CrossRefPubMedGoogle Scholar
  11. 11.
    Minoo P, Zlobec I, Baker K, et al. Prognostic significance of mammalian sterile20-like kinase 1 in colorectal cancer. Mod Pathol. 2007;20:331–8.CrossRefPubMedGoogle Scholar
  12. 12.
    Kim TS, Lee DH, Kim SK, Shin SY, Seo EJ, Lim DS. Mammalian sterile 20-like kinase 1 suppresses lymphoma development by promoting faithful chromosome segregation. Cancer Res. 2012;72:5386–95.CrossRefPubMedGoogle Scholar
  13. 13.
    Yoneda A, Lendorf ME, Couchman JR, Multhaupt HA. Breast and ovarian cancers: a survey and possible roles for the cell surface heparan sulfate proteoglycans. J Histochem Cytochem. 2012;60:9–21.PubMedCentralCrossRefPubMedGoogle Scholar
  14. 14.
    Penault-Llorca F, Viale G. Pathological and molecular diagnosis of triple-negative breast cancer: a clinical perspective. Ann Oncol. 2012;23:19–22.CrossRefGoogle Scholar
  15. 15.
    Oh HJ, Lee KK, Song SJ, et al. Role of the tumor suppressor RASSF1A in Mst1-mediated apoptosis. Cancer Res. 2006;66:2562–9.CrossRefPubMedGoogle Scholar
  16. 16.
    Zhou D, Conrad C, Xia F, et al. Mst1 and Mst2 maintain hepatocyte quiescence and suppress hepatocellular carcinoma development through inactivation of the Yap1 oncogene. Cancer cell. 2009;16:425–38.PubMedCentralCrossRefPubMedGoogle Scholar
  17. 17.
    Avruch J, Zhou D, Fitamant J, Bardeesy N, Mou F, Barrufet LR. Protein kinases of the Hippo pathway: regulation and substrates. Semin Cell Dev Biol. 2012;23:770–84.PubMedCentralCrossRefPubMedGoogle Scholar
  18. 18.
    Lehtinen MK, Yuan Z, Boag PR, et al. A conserved MST-FOXO signaling pathway mediates oxidative-stress responses and extends life span. Cell. 2006;125:987–1001.CrossRefPubMedGoogle Scholar
  19. 19.
    Song H, Mak KK, Topol L, et al. Mammalian Mst1 and Mst2 kinases play essential roles in organ size control and tumor suppression. Proc Natl Acad Sci USA. 2010;107:1431–6.PubMedCentralCrossRefPubMedGoogle Scholar
  20. 20.
    Zhou D, Zhang Y, Wu H, et al. Mst1 and Mst2 protein kinases restrain intestinal stem cell proliferation and colonic tumorigenesis by inhibition of Yes-associated protein (Yap) overabundance. Proc Natl Acad Sci USA. 2011;108:1312–20.CrossRefGoogle Scholar
  21. 21.
    Seidel C, Schagdarsurengin U, Blumke K, et al. Frequent hypermethylation of MST1 and MST2 in soft tissue sarcoma. Mol Carcinog. 2007;46:865–71.CrossRefPubMedGoogle Scholar
  22. 22.
    Paplomata E, O'Regan R. New and emerging treatments for estrogen receptor-positive breast cancer: focus on everolimus. Ther Clin Risk Manag. 2013;9:27–36.PubMedCentralPubMedGoogle Scholar
  23. 23.
    Bostner J, Karlsson E, Pandiyan MJ, et al. Activation of Akt, mTOR, and the estrogen receptor as a signature to predict tamoxifen treatment benefit. Breast Cancer Res Treat. 2013;137:397–406.PubMedCentralCrossRefPubMedGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2013

Authors and Affiliations

  • Xiaoyan Lin
    • 1
    • 2
    • 3
  • Fengfeng Cai
    • 2
    • 4
  • Xiaoyan Li
    • 3
  • Xiaoli Kong
    • 3
  • Cheng Xu
    • 2
  • Xiaoming Zuo
    • 5
  • Qifeng Yang
    • 3
  1. 1.Department of Oncology, Qilu HospitalShandong UniversityJinanChina
  2. 2.Department of Breast Surgery, Yangpu HospitalTongji UniversityShanghaiChina
  3. 3.Department of Breast Surgery, Qilu HospitalShandong UniversityJinanChina
  4. 4.Department of Biomedicine, Women’s HospitalBasel UniversityBaselSwitzerland
  5. 5.Department of Pathology, Yangpu HospitalTongji UniversityShanghaiChina

Personalised recommendations